VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate ProgramGlobeNewsWire • 05/05/25
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsBusiness Wire • 03/18/25
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics ConferenceBusiness Wire • 12/16/24
Long Assets On Path To Creating Significant Value, Shorting Remains Very ChallengingSeeking Alpha • 08/06/24
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of ImmunologyBusiness Wire • 06/03/24
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston SummitBusiness Wire • 05/15/24